



ASX / Media Release
8 October 2015

Key management appointments in preparation for commercialisation

SYDNEY, 8th October, 2015: OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to announce details of two new key appointments to its senior management team in preparation for the commercialisation of the Company's OncoSil™ localised radiation treatment for cancer.

Mr David James appointed Global Head of Manufacturing Operations

Mr David James has been appointed the Company's Global Head of Manufacturing Operations on a full-time basis effective from 5 October 2015, after initially working in the role in a part-time consultancy capacity since February.

Mr James is a highly experienced pharmaceutical manufacturing operations executive with more than 20 years' experience in this field, including six years with leading cancer treatment company Sirtex Medical (ASX: SRX) as Global Operations Manager.

His full-time appointment coincides with OncoSil Medical's increased focus on the manufacture of OncoSil™ for use in upcoming clinical trials and also in commercial sales of the product, and is a significant hire for the Company. Mr James will play a key role in all manufacturing-related functions and requirements for OncoSil™ and ultimately in the commencement of production of OncoSil™.

During his time at Sirtex he was responsible for managing the global operations team including production, logistics, customer service and engineering. This included responsibility for the design, construction and commissioning of Sirtex's first in-house manufacturing plant in Wilmington DC, in the US.

Mr James has an Masters in Business and Technology from the University of New South Wales and is a Chartered Chemist with the Royal Australian Chemical Institute

Dr Greg Rogers appointed Manufacturing Engineering Manager

The Company is also pleased to advise of the appointment of Dr Greg Rogers as Manufacturing Engineering Manager, effective from 2 November 2015.

Dr Rogers has more than 27 years experience in leadership, operations, quality control and change management roles in the medical device and diagnostics sectors, as well as the fast-moving consumer goods (FMCG) and heavy engineering industries. His is another key appointment to Company's manufacturing management team.

Dr Rogers' previous roles include General Mananger Manufacturing for medical device company, Ingeneus Pty Ltd, where he was responsible for developing the manufacturing capability for its hand held and

ophthalmic lasers for Australian, US and European markets. He also been Regulatory and Quality Manager for sleep apnoea medical device company, SomnoMed Ltd (ASX: SOM).

Dr Rogers also previously held a variety of management roles with global sleep disorder solutions company ResMed Inc. (ASX and NYSE: RMD) in Australia from 2000-2005, including Director of Manufacturing where he managed 220 staff.

He has also worked for Australia's Therapeutic Goods Administration and was Executive Manager for Downer Rail, where he was responsible for reducing costs in train repair and new train build projects, among other senior roles.

Dr Rogers has a Ph.D. in Biomedical Engineering from the University of New South Wales, a B.E. in Mechanical Engineering (Honours) from the University of Sydney and a B.Sc. in Pure and Applied Mathematics from the University of Sydney.

Commenting on the appointments OncoSil Medical CEO, Daniel Kenny said:

"Both these appointments are pivotal additions to OncoSil Medical's senior management team and will be integral to the Company as it transitions its focus from the development phase to the commercialisation of OncoSil™ for the treatment of pancreatic and primary liver cancer (HCC). On behalf of the OncoSil team I would like to welcome David and Greg and we look forward to their strong, positive contributions as we continue to progress our commercialisation plans."

ENDS

Contact:

Mr Daniel Kenny
Chief Executive Officer and Managing Director

E: daniel.kenny@oncosil.com.au

T: +61 2 9223 3344

James Moses
Mandate Corporate

E: james@mandatecorporate.com.au

M: +61 420 991 574

T: +61 2 8211 0612

About OncoSil Medical Ltd

OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian Lifesciences company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical's lead product is OncoSil™ with the first target indication being pancreatic cancer. OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumours outside of pancreatic cancer. FDA and CE Mark approval for pancreatic cancer is the core focus of OncoSil Medical.

Pancreatic Cancer

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

Hepatocellular carcinoma liver cancer

Hepatocellular carcinoma (HCC) is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. It's very poor prognosis makes HCC the third leading cause of cancer related mortality responsible for approximately 600,000 deaths annually. Hepatocellular carcinoma can be cured by surgery or transplantation. The vast majority of patients with HCC have disease which is too advanced for surgical intervention and as a consequence survival ranges from a few months to two or more years depending on the liver function at diagnosis and the extent of tumour invasion. The value of the hepatocellular cancer (HCC) market is expected to triple in size to \$1.4b by 2019.

References

- Global Industry Analysts 2010
- BIOSDP-201. A single dose, single centre open label Phase I/II Safety Study in Hepatocarcinoma
- Venook et al. The incidence of Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. The Oncologist; 15 Supplement 5-13
- <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/pancreatic-cancer-statistics>
- <http://www.datamonitorhealthcare.com/hepatocellular-cancer-market-to-treble-in-size-by-2019>
- <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/liver-cancer-statistics>